Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? Reply
- 1 October 2020
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 72 (4), 1498-1499
- https://doi.org/10.1002/hep.31268
Abstract
We thank Drs. Chen and Vitetta for their letter regarding our manuscript describing our phase 2 study of the nonsteroidal farnesoid X receptor (FXR) agonist cilofexor in non‐cirrhotic patients with primary sclerosing cholangitis (PSC).1 As the authors point out, decreased levels of certain bile acid species secondary to FXR agonism could in theory worsen the colitis commonly associated with PSC. They propose that these deleterious effects could be mitigated by the addition of butyrate, a short chain fatty acid that serves as a key fuel source for colonic epithelial cells and is used as therapy in disorders such as diversion colitis.This publication has 4 references indexed in Scilit:
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitisJournal of Hepatology, 2020
- The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisHepatology, 2019
- Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel diseaseGut, 2011